Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain fatigue after thyroid disease: immune system may be to blame

NCT ID NCT05678374

Knowledge-focused Sponsor: Vastra Gotaland Region Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 15, 2026 · Updated 2 times

Summary

This study investigates why some people with Graves' disease continue to feel mentally fatigued even after their thyroid levels return to normal. Researchers will compare blood and spinal fluid from 180 participants—60 with mental fatigue, 60 without, and 60 healthy controls—to find antibodies that may attack brain proteins. The goal is to uncover whether an autoimmune reaction is causing the fatigue, which could lead to better diagnosis or treatments in the future.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could identify specific immune markers that cause mental fatigue in Graves' disease, pointing toward future treatments.
What could go wrong
This is an early observational study, not a treatment trial. It may not find clear markers, and any findings will need validation in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

94 people

The number who actually took part.

Started

Oct 2019

Finished

Aug 2026

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients are recruited from the both previous patients at the Endocrine outpatient Clinic at Sahlgrenska University Hospital in Gothenburg and from advertising. They are invited to a web based screening form where the ones eligible are contacted by study personal and eligibility criteria are checked again. Controls are recruited by the same way and by contacting a random sample from the population registration (based on Swedish social security number). Groups are matched for age, educational level and smoking habits.

Ages

18 to 72 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * If patient: Graves' disease with positive TSH-receptor antibodies and thyroid hormones above the upper reference limit at diagnosis * Diagnosis15 to 60 months ago. If recidive both episodes must have occurred within 15 months to 60 months. * Thyroid hormones within normal range without anti thyroid drugs * If control: No thyroid disease * Patient and control without mental fatigue: Mental Fatigue Score ≤8 (cut off 10.5) * Patient with mental fatigue: Mental Fatigue Score \>13 and debut of symptoms of mental fatigue in parallel with debut of Graves' disease, without other obvious cause Exclusion Criteria * Person unable to follow protocol * Multiple sclerosis, myalgic encephalomyelitis/chronic fatigue syndrome, any other neurological disease * Traumatic brain injury with unconsciousness * Other disease strongly associated with fatigue * Pregnancy and breast-feeding * On-going or recent systemic treatment with steroids * Radioiodine therapy within the last 18 months

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Autoimmune diseases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

autoimmune disease endocrine exophthalmos Graves disease Graves Ophthalmopathy Mental Fatigue thyroid gland disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Autoimmune diseases Graves disease Graves ophthalmopathy Mental fatigue Thyroid diseases

Contacts and locations

Locations

  • Department of Endocrinology, Sahlgrenska University Hospital

    Gothenburg, 41346, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.